LANRAPLENIB SUCCINATE

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	2C23H25N9O.3C4H6O4
Molecular Weight	1241.2727
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CCC(O)=O.OC(=O)CCC(O)=O.OC(=O)CCC(O)=O.NC1=NC(=CN=C1)C2=CN3C=CN=C3C(NC4=CC=C(C=C4)N5CCN(CC5)C6COC6)=N2.NC7=NC(=CN=C7)C8=CN9C=CN=C9C(NC%10=CC=C(C=C%10)N%11CCN(CC%11)C%12COC%12)=N8

InChI

InChIKey=SUXNLHAGYIRFJQ-UHFFFAOYSA-N

InChI=1S/2C23H25N9O.3C4H6O4/c2*24-21-12-25-11-19(28-21)20-13-32-6-5-26-23(32)22(29-20)27-16-1-3-17(4-2-16)30-7-9-31(10-8-30)18-14-33-15-18;3*5-3(6)1-2-4(7)8/h2*1-6,11-13,18H,7-10,14-15H2,(H2,24,28)(H,27,29);3*1-2H2,(H,5,6)(H,7,8)

HIDE SMILES / InChI

Molecular Formula	C4H6O4
Molecular Weight	118.088
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C23H25N9O
Molecular Weight	443.5043
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

C_max

Value	Dose	Analyte	Population
134.4 ng/mL CLINICAL TRIAL clinicaltrials.gov/ct2/show/results/NCT02959138	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	LANRAPLENIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
131.6 ng/mL CLINICAL TRIAL clinicaltrials.gov/ct2/show/results/NCT02959138	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	LANRAPLENIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
118 ng/mL CLINICAL TRIAL clinicaltrials.gov/ct2/show/results/NCT02959138	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	LANRAPLENIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
2478.7 ng × h/mL CLINICAL TRIAL clinicaltrials.gov/ct2/show/results/NCT02959138	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	LANRAPLENIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2153 ng × h/mL CLINICAL TRIAL clinicaltrials.gov/ct2/show/results/NCT02959138	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	LANRAPLENIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2223.4 ng × h/mL CLINICAL TRIAL clinicaltrials.gov/ct2/show/results/NCT02959138	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	LANRAPLENIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
20.4% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32292557/			LANRAPLENIB plasma	Homo sapiens

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:05:34 GMT 2025` Edited by `admin` on `Mon Mar 31 18:05:34 GMT 2025`
Record UNII	QJ2PS903VZ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LANRAPLENIB SUCCINATE

Official Name

English

GS-SYK SUCCINATE

Preferred Name

English

BUTANEDIOIC ACID, COMPD. WITH 6-(6-AMINO-2-PYRAZINYL)-N-(4-(4-(3-OXETANYL)-1-PIPERAZINYL)PHENYL)IMIDAZO(1,2-A)PYRAZIN-8-AMINE (3:2)

Systematic Name

English

6-(6-Aminopyrazin-2-yl)-N-{4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl}imidazo[1,2-a]pyrazin-8-amine succinate (2:3)

Systematic Name

English

LANRAPLENIB SESQUISUCCINATE

Common Name

English

LANRAPLENIB SUCCINATE [USAN]

Common Name

English

Code System Code Type Description

CAS

1800047-00-0